Log In
BCIQ
Print this Print this
 

Ongentys, opicapone (ONO-2370) (formerly BIA 9-1067)

  Manage Alerts
Collapse Summary General Information
Company Bial-Portela & Ca. S.A.
DescriptionPeripheral, selective and reversible catechol-O-methyl-transferase (COMT) inhibitor that increases L-dopa plasma levels
Molecular Target Catechol-O-methyl-transferase (COMT)
Mechanism of ActionCatechol-O-methyl-transferase (COMT) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation EU - Standard Review (Treat Parkinson's disease (PD))
PartnerOno Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/06/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today